Your Messages Inbox
Your Article Summary
See Latest ArticlesDevelopment of drugs against hormone-refractory prostate cancer
Drug Development Research, 12/29/08
Kageyama Y - The development of novel drugs for prostate cancer refractory to androgen deprivation therapy has been of great interest due to the lack of effective treatment modalities that can prolong the survival of such patients. The recent introduction of docetaxel-based combination chemotherapy has been a breakthrough with a modest, but significant, survival benefit. However, the improved survival period measured in months is far from ideal considering the non-negligible adverse events associated with docetaxel. Thus, numerous preclinical and clinical studies have been conducted to explore more favorable approaches to hormone-refractory prostate cancer.
Related Articles
Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients
International Urology and Nephrology, 11/13/09
Relevance Score: 82%
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Relevance Score: 72%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09
Relevance Score: 71%
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Major Study Finds Anti-HIV Gel Ineffective Among Women
National Institute of Allergy and Infectious Disease - News, 12/17/09
Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09
New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09
Article Search
Sponsor